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The availability of monoclonal antibodies specific for tumor-associated cell surface 
markers has resulted in renewed interest in cancer serotherapy. In fact, several clinical 
trials have been conducted  (reviewed in ref.  1),  but successful tumor remission has 
been achieved in only one case (2).  A  crucial problem for specific immunotherapy is 
the potential escape of antigen-deficient variants from immune control. We recently 
described a  model  system  in  which  mice could  be  protected  from  challenge with 
L5178Y lymphoma cells by passive infusion of a monoclonal antibody specific for the 
glycolipid asialo GM2  (gangliotriosylceramide; GalNacfll ~  4Galfll --*  4Glcfil 
ceramide), which was present on the lymphoma cell surface (3).  In a  few antibody- 
treated  mice,  ascites  tumor cells eventually proliferated that  were  deficient in  the 
chemical  quantity of  asialo  GM2  (3).  The  purpose  of  the  present  study  was  to 
demonstrate that  these  emergent  cells  were  in  fact  variants of  the  cells  used  for 
challenge and to characterize the display of the glycolipid antigen on these cells. 
Materials and Methods 
Mice.  Male DBA/2 and CBA mice (8 wk old) were obtained from The Jackson Laboratory, 
Bar Harbor, ME. Male (BALB/c X DBA/2)F1 (CD2. FI) mice (8 wk old) were obtained from 
Laboratory Supply, Indianapolis, IN. 
Tumor Cell Lines.  The derivation of a  variant of the DBA/2 lymphoma cell  line L5178Y, 
designated subclone 1A1, has been described elsewhere  (4). This variant was used as target cell 
for  serotherapy  (3)  because it  contained a  high  level  of asialo GM2.  During the course of 
serotherapy studies, ascites tumor cells were removed from both untreated and antibody-treated 
mice and returned to tissue culture for analysis. Cells were removed from an untreated DBA/ 
2 mouse 71 d after challenge (designated IA1-TU cells) and from an untreated CD2.F1 mouse 
56 d after challenge (1A1-245 cells). The following cell lines were isolated from antibody-treated 
DBA/2 mice on the indicated day after challenge: 1A1-616 (day 61), 1A1-G3AF7 (day 76), and 
1AI-1010  (day 100). 
Antibodies.  BALB/c monoclonal IgM and IgG3 antibodies specific  for asialo GM2  have 
been characterized previously (5). Mouse alloantiserum obtained through the courtesy of Dr. 
John G. Ray, National Institutes of Health, Bethesda, MD, was specific for the H-2D  a end of 
the H-2  a complex and was designated NIH serum D-13. 
Serotherapy Protocol.  As  previously described (3), the  protocol consisted of intraperitoneal 
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challenge of DBA/2 mice with 10  s 1A1 or 105  1A1-G3AF7 cells on day 0. Mice were treated 
intraperitoneally on  days  1,  3,  7,  and  10  with  0.1  ml  of ascites  fluid  from  mice bearing 
hybridoma cells that  produce monoclonal IgG3 anti-asialo GM2  (3  mg antibody per ml of 
pooled ascites fluid). Due to lethal Sendai virus infections of DBA/2 mice in our mouse colony, 
the identical serotherapy protocol was also conducted in CD2. F1 mice. 
Karyotype Analysis.  Chromosome preparations were made as described by Miller et al.  (6). 
This method has been used previously for the analysis of other L5178Y lymphoma variants (7). 
Effector Cells.  The source of natural killer (NK) cells was the spleens of adult CBA mice that 
had received 100/~g poly I:C (Sigma Chemical Co., St. Louis, MO) intraperitoneally  in 0.1 ml 
RPMI 1640 1 d earlier. 
Microcytotoxicity Assays.  Target cells were 5~Cr labeled as previously described (8), assays were 
performed in V-bottomed microtiter plates (Linbro Scientific, Hamden, CT), and all dilutions 
were made with RPMI containing i0% newborn calf serum (Sterile Systems, Logan, UT). For 
antibody-complement  assays, each well received 0.05 ml antiserum, 0.05 ml of a  1:8 dilution of 
either native or heated (56°C, 30 rain) English smooth hair guinea pig serum as a complement 
source, and 0.1 ml containing  2 X 104 labeled target cells. Plates were incubated for 45 rnin at 
37°C, centrifuged at 250 g for I rain, and 0.1 ml of the cell-free supernatant was measured for 
~ICr content in a gamma scintillation  counter. 
For NK cell assays, effector  cells and 2 ×  104 ~XCr-labeled target cells were combined in a 
total volume of 0.2 ml per well. The plates were centrifuged at 250 g for 1 min both before and 
after a 4-h incubation  at 37°C, and then 0.1 ml of the supernatant was assayed for SICr content. 
Specific lysis was calculated relative to the spontaneous release observed in wells containing 
target cells alone according to the following equation: percent specific  lysis =  ([test  cpm - 
spontaneous cpm]/[cpm released by three cycles of freeze-thaw])  ×  100. Freeze-thawed cells 
released ~80% of their total radioactivity. 
Flow Microfluorometry.  Cells were washed twice and then incubated for 60 min at 4°C with 
a 1:10 dilution of mouse IgM anti-asialo  GM2 ascites fluid that had been heated at 56 °, 30 min 
d  or a  1:25 dilution of anti-H2  serum (NIH serum D-13).  After three washes,  the cells were 
incubated for  60  min at  4°C  with  a  1:50  dilution of fluorescein-labeled goat  anti-mouse 
immunoglobulin (N.  L.  Cappel Laboratories, Cochranville, PA). After two washes,  the cells 
were analyzed on a  fluorescence-activated cell sorter (FACS IV; B-D FACS Systems Becton, 
Dickinson & Co., Sunnyvale, CA). 
Results 
Cytogenetic Analysis.  As previously described (3), serotherapy with IgG3 anti-asialo 
GM2  protected  the  majority of mice  from  challenge with  an  asialo GM2-positive 
variant  (1A1)  of L5178Y  lymphoma cells.  However,  in  a  few  cases  asialo  GM2- 
deficient ascites tumor cells arose after a  prolonged period (3). To determine whether 
these ascites tumor cells were progeny of the ceils used  for  initial challenge rather 
than having been newly induced in the host, we searched for abnormal chromosomal 
markers common to both original and emergent cells. 
The  original  1A1  cells used  for  challenge as  well  as  the  cells derived  from  two 
antibody-treated mice had  more  than  the  diploid number of chromosomes, often 
about 50  60 chromosomes per cell. These included copies of normal chromosomes, as 
well as structurally altered or marker chromosomes. Fig.  1 demonstrates that several 
marker chromosomes were found to be common to all three cell lines. These results 
indicate that these lines were closely related and strongly suggest that the cells arising 
after antibody treatment were progeny of the original 1A1 cell inoculum. 
Antigen Display on Lymphoma  Variants.  Flow microfluorometry was used to examine 
the  display of asialo GM2  and H-2  a on  1Al  and ascites tumor cells derived  from 
untreated and anti-asialo GM2-treated mice (Fig. 2).  All cell lines were cultured in 
vitro  for  at  least  1  mo  before  analysis to  eliminate both  host  cells  and  residual 26  GLYCOLIPID-DEFICIENT LYMPItOMA  CELL VARIANTS 
Fic.  1.  Quinacrine-stained abnormal,  or marker, chromosomes  from L5178Y  variant cell lines. 
Top row, subclone 1AI cells used for challenge in serotherapy experiments. Middle row, subclone 
1A1-G3AF7 cells harvested from a  mouse 76 d  after challenge with  106 subclone  1A1  cells and 
treatment  with IgG3  anti-asialo GM2.  Bottom row, subclone  1A1-616 cells harvested 61  d  after 
challenge and treatment. The largest  marker is a biarmed chromosome that includes two copies of 
the X  (probably plus some duplicated material). The third largest  is a chromosmne in which both 
arms are copies of number 10. Tim sixth and seventh chromosomes from the left are identical; they 
are copies of number 2 with an elongated centron,  eric region.  Tbe eighth and ninth from  the left 
are again identical representing a number 11 with material added to the distal end. 
antibody  that  could  have covered or modulated  tumor  cell surface  determinants.  In 
contrast  to the uniform,  positive reaction  of 1A1  cells with anti-asialo GM2,  <5%  of 
cells from  antibody-treated  mice  (1A1-G3AF7  ,  1A1-616,  and  1AI-1010)  displayed 
detectable asialo GM2.  Interestingly, cells from untreated  mice represented a  mixture 
of asialo GM2-positive and  -negative cells; 49% of I A I-TU cells and  25% of 1A 1-245 
cells reacted  with  anti-asialo  GM2.  Unlike  the  dramatic  alterations  in  asialo  GM2 
display,  the expression of H-2  a on these cell lines was  virtually unchanged  from  that 
of 1A1  cells. Thus,  in vivo passage of 1A1  cells appeared  to result  in selection of cells 
deficient in asialo GM2  but  not H-2  a determinants,  particularly in mice treated  with 
anti-asialo GM2  (see Discussion). 
To determine the stability ofasialo GM2  display on the cells derived from untreated 
mice,  1A1-TU cells were  stained  with  anti-asialo  GM2  and  then  sorted  on  the  flow 
cytometer to separate asialo GM2-positive and -negative populations. These cells were 
returned  to  culture  for  10  d  and  then  reanalyzed  for  asialo  GM2  expression.  Fig.  3 
indicates  that  each  population  retained  its  original  asialo  GM2  display  and  thus 
represented  stable subsets  of cells with regard  to asialo GM2  expression. 
The  cell variants  were also compared  for  their susceptibility  to  antibody-comple- 
ment-mediated  lysis. The purpose of this experiment was not only to obtain additional 
evidence  regarding  the  antigenic  display  of these  cells,  but  also  to  determine  their 
sensitivity  to  lyric effector mechanisms.  IgM  anti-asialo  GM2  ascites  fluid  was  used anti-asialo  GM2  anti-H2 
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Fro.  2.  Flow microfluorometry of LS178Y lymphoma cell lines with anti-asialo GM2  and  anti- 
H-2  'l, Lymphoma cell variants were labeled with IgM anti-asialo GM2 or mouse anti-H-2  ¢1 serum 
followed by fluoresceinated goat anti-mouse immunoglobulins and  analyzed on  the fluorescence- 
activated cell sorter as described in Materials and Methods.  IA1, cells used for challenge; 1A1-TU 
and  1AI-24.5, ascites tumor cells that arose in untreated mice; and  1A1-G3AF7, 1Al-616, and  1A1- 
1010, ascites tumor cells thai arose in mice treated with lgG3 anti-asialo GM2. Abscissa, cell size as 
determined by light scatter; ordinate, fluorescence. 
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Fie;. 3.  Flow microfluorometricanalysis of the stability  ofasialo GM2 expression on IA1-TU cells. 
1A1-TU cells were labeled with lgM anti-asialo GM2 followed by fluoresceinated goat anti-mouse 
immunoglobulins and sorted on  a  FACS-IV under sterile conditions. Asialo GM2 negative cells 
sorted  from fluorescence channels  1-5 and  positive cells obtained from channels  114-255 were 
grown in cultare for I0 d and then reanalyzed by flow microfluorometry. Upper curve, asialo GM2- 
positive population, and lower curve, asialo GM2-negative population; ~50,000 ceils were anatyzed 
from each population. 
for  this  assay  rather  than  the  IgG3  ascites  because  the  former  had  a  titer  for 
complement-dependent cell lysis 10,000-fold higher than the latter. The results of lysis 
by anti-asialo GM2  plus complement  (Table I) were consistent with the flow micro- 
fluorometry data. Cells from antibody-treated mice (1A1-G3AF7, 1A1-616, and  1Al- 
l010)  were highly resistant, whereas lysis of the  two cell lines from  untreated  mice 
(1A1-TU  and  1A1-245)  roughly  corresponded  to  the  percentage  of  positive  cells 
determined by cell sorter analysis (Fig. 2). However, the level of antibody required to 
achieve maximal  lysis suggested that  the cells from  untreated  mice might  be  more 
resistant to  the  action of complement than  1A1  cells. A  comparison  of the  variants 
with  regard  to  the  effect  of  anti-H-2  d  serum  revealed  an  approximately  two-  to 
fourfold difference in  sensitivity to complement-mediated cytolysis (Table I).  These 
differences appeared to be unrelated to the origin of each cell line; of the three cell 
lines from antibody-treated mice, one (1A1-G3AF7) was highly sensitive, whereas the 
other  two  (1A1-616  and  1AI-1010)  were  much  more  resistant.  As  H-2  a  expression 
determined by flow  cytometry was  virtually identical among  the  variants  (Fig.  2), 
these results suggested differences in susceptibility to complement action. 
Susceptibility  to NK Cell Attack.  Variants of L5178Y cells have been shown to differ 
in their susceptibility to NK cell lysis (4, 8, 9). The possibility existed, therefore, that 
the cells that eventually arose in  a  few antibody-treated mice might  have been  able 
to proliferate because they could resist NK cell attack. Table II indicates that  these 
cell lines were only slightly less sensitive to NK cell lysis than the highly sensitive 1A1 
cells. For comparison, data are included in Table II  for the NK-resistant variant of 
L5178Y  designated clone 27AV  (8).  The  data do not  support  a  role for NK  cells in 
the selection of ascites tumor cells that survived anti-asialo GM2 serotherapy. 
Resistance  of Emergent  Cells to Serotherapy.  The data described above suggest that the 
ascites cells that eventually arose in mice after 1A 1 cell challenge and anti-asialo GM2 YOUNG  ET  AL. 
TABLE  I 
Complement-mediated Cytotoxicity of L5178 Y Cell  Variants by Anti-Asialo 
GM2 Ascites and Anti-H-2  d Serum* 
Monoclonal IgM anti-asialo  GM2 ascites fluid 
Percent specific cytolysis at ascites dilution 
L5178Y variant 
10  6  10-5  10-4  10  a  10  2 
1AI  11.2  50.8  88.5  90.9  97.3 
IA1-TU  0  1.6  7.0  22.5  34.5 
1A1-245  2.3  2.5  8.7  19.4  26.9 
1A 1-G3AF7  1.4  0.3  1.2  3.4  3.4 
1A1-616  1.3  0.8  0.4  0.4  0 
[AI-10IO  0.2  0  0  0  0 
Mouse anti-H2 a serum (NIH serum D-13) 
L5178Y variant 
Percent specific cytolysis at serum dilution 
1:640  1:320  1:160  1:80  1:40 
1AI  43.6  82.7  91.8  95.9  97.2 
1A1-TU  15.3  52.7  75.3  83.2  86.1 
1A1-245  11.1  54.3  80.5  84.9  88.1 
1A 1-G3AF7  49.2  75.0  84.2  86.0  89.3 
1A1-616  2.8  11.9  34.2  55.5  69.5 
1A 1-1010  4.2  30,9  59.4  77.7  84.9 
* Microcytotoxicity  assays were  performed  on  ~Cr-labeled  target  cells  as 
described in Materials and Methods. Percent specific cytolysis in the presence 
of antibody alone or antibody plus heated guinea pig serum (as the comple- 
ment source) was <2% in all cases. 
29 
TABLE  II 
Susceptibility  to NK Cells of L5178Y Lymphoma  Cell Variants* 
L5178Y variant 
Percent specific eytolysis by NKcells at 
effector/target cell  ratio 
12:1  25:1  50:1  100:1 
Experiment 1 
1A1  15.2  25.7  38.7  52,5 
1A1-245  10.7  17.9  29.9  43.3 
1A1-G3AF7  13.8  23.4  37.7  47.7 
Clone 27AV  3.1  3.9  4.4  5.6 
Experiment 2 
1A1  11.0  18.3  29.9  43.2 
1A l-TU  8.2  15.6  24.4  38.6 
1AI  616  8.2  15.2  26.1  37.9 
1AI  1010  7.3  12.6  19.0  31.7 
* Microcytotoxicity  assays were  performed  on  SlCr-labeled  target  cells 
described in Materials and Methods. 
as 
treatment  may  have  been  able  to withstand  serotherapy  because  they  were deficient 
in asialo GM2.  To  directly test this point, mice were challenged  with  105  1A1-G3AF7 
cells  and  then  treated  with  IgG3  anti-asialo  GM2  ascites  fluid.  Serotherapy  had  no 30  GLYCOLIPID DEFICIENT LYMPHOMA  CELL  VARIANTS 
111 63 IF7 IASIALO 61R2 UGFICIEHTI 
IOO 
75 
25 
2O  AO  60  8O  100 
DAYS AFTER TUMOR CHALLENGE 
FJc.  4.  Failure of serotherapy protocol  to  protect  against  challenge  with  asia]o GM2-deficient 
lymphoma  cells. L5178Y  lymphoma  subclone 1A 1  -G3AF7 cells arose in a mouse 76 d after challenge 
with subclone IA1 ceils and treatment with IgG3 anti-asialo GM2. CD2. Fz mice were challenged 
with  l0  s  1AI-G3AF7 ceils  intraperitoneally on day 0. One group was treated intraperitoneal[y on 
days 1,3, 7, and 10 with 0. i m[ ascites fluid containing IgG3 anti-asialo GM2 (0); untreated control 
group ~).  Each group contained six mice. 
effect  on  survival  of these  mice  (Fig.  4),  indicating  that  these  cells  were  able  to 
proliferate despite the immune pressures present in antibody-treated mice. 
Discussion 
Considerable effort  is  presently  being devoted  to  the  production  of monoclonal 
antibodies directed against human tumor-associated cell surface markers.  Several of 
these  antibodies  have been  found to  react  with  specific glycolipids (10  13). These 
antibodies may prove useful not only for cancer diagnosis but  also therapy  (1). An 
obvious limitation of such specific serotherapy would be the appearance of antigen- 
negative tumor cells,  which could avoid treatment. The generation of such variants 
is a  predictable and essential element in the phenomenon of tumor progression (14) 
by  which  cancer cells  are  able  to  evade  any  selective  pressure.  Thus,  it  was  not 
surprising that we detected asialo GM2 deficient variants arising in a few of the mice 
that  had  been  challenged with  1A1  cells  and  treated  with  monoclonal IgG3 anti- 
asialo  GM2  (3). Similarly,  Bernstein  and  Nowinski  (15)  found  Thy-l.l-negative 
leukemia  cell  variants  in  mice  that  had  been  challenged  with  Thy-l.l-positive 
leukemia cells and treated with anti-Thy-1.1-specific monoclonal antibodies. 
The unexpected finding of the present  study was the appearance of asialo GM2- 
deficient tumor cells in mice that had  not been treated with anti-asialo GM2 (1AI- 
TU  and  1A1-245 cells;  Fig.  2).  Other  groups  have  described  alterations  in  tumor 
antigen expression that  were due to shielding of cell surface determinants by other 
macromolecules (16,  17). This  phenomenon is  unlikely  in  our system  because  H-2 
antigen display on the variants was unchanged (Fig.  2) and the chemical quantity of 
asialo GM2 on 1A1-TU cells, about half that of 1A1 cells  (3), matched the percentage 
of cells that were reactive with anti-asialo GM2  (Fig.  2).  During in vitro culture for 
>2 roD, >96% of 1A 1 ceils remained asialo GM2 positive as deterrnined by cell sorter 
analysis. The expansion of asialo GM2-deficient cells  during a similar period of time 
in  vivo  must  have  been  the  result  of selective  pressure.  The  selection  process  was 
specific, in  that  H-2 antigen expression was unchanged on the variants;  thus, asialo 
GM2-negative  cells  may  be  the  product  of a  host  immune  response  against  the 
glycolipid. We are currently attempting to detect such a  response. Our preliminary YOUNG ET AL.  31 
results indicate that whereas CD2.F1  mice can be immunized to produce anti-IA1 
cell  antibodies,  none  of those  antibodies  is  specific  for  asialo  GM2  (unpublished 
observation). Alternatively, the selective pressure may have been directed against a 
complex of membrane determinants. It is unlikely that such a complex was the result 
of viral contamination, because the subclone  1A 1 cells tested negative in a  screening 
for 12 viral contaminants including Sendai virus (data not shown). 
The tumor cells that emerged from both antibody-treated and untreated mice were 
only slightly less sensitive to NK cell attack than  1A 1 cells (Table II), suggesting that 
resistance to NK lysis was not a  critical element in  the phenotype of the cells that 
survived. However, it is possible that NK cells may act in concert with more specific 
immune mechanisms to decrease the tumor load.  In fact, Kawase et al.  (9)  recently 
reported that modulation of NK activity effected the tumorigenicity of other L5178Y 
subclones. 
Weinhold  et  al.  (18)  described  a  tumor  dormant  state  established  in  L5178Y 
immunized and challenged mice in  which  a  prolonged period of clinical  normalcy 
was followed by rapid tumor outgrowth. Cytotoxic T  cells reactive with L5178Y ceils 
were detectable during  the early period of tumor dormancy.  The tumor cells that 
eventually emerged expressed eightfold less serologically detectable tumor associated 
antigens than the original cells used for challenge. Our serotherapy system may have 
similar antitumor mechanisms at work that are directed against a  battery of tumor- 
associated antigens, perhaps including asialo GM2. These host defenses, when com- 
bined with additional anti-tumor effects mediated by IgG3 anti-asialo GM2, may be 
sufficient to eradicate the tumor completely in the majority of mice. 
Summary 
Mice challenged with L5178Y lymphoma cells expressing high levels of the glyco- 
lipid  asialo  GM2  (gangliotriosylceramide)  were  protected  from  tumor  growth  by 
passive administration of a  monoclonal antibody specific for the glycolipid; in a  few 
antibody-treated mice, ascites cells eventually proliferated which contained a reduced 
chemical quantity of the glycolipid antigen (3). We now report that the cells emerging 
from antibody-treated mice had abnormal marker chromosomes identical to those in 
the cells used  for challenge,  indicating that  the emergent cells were progeny of the 
challenge inoculum.  Flow cytometric analysis revealed that  asialo GM2  was unde- 
tectable  on  the  surface  of >95%  of the  tumor  cells  from  antibody-treated  mice, 
whereas surface display of H-2 determinants was unchanged  from that  of the cells 
used for challenge. Tumor cells arising in challenged but untreated mice consisted of 
a  mixture  of asialo  GM2-positive  and  -negative  cells,  indicating  the  presence  of 
selective pressures in these mice as well. None of the cells taken from tumor bearing 
mice differed significantly from the challenge cells in  their susceptibility to natural 
killer cell attack, suggesting that resistance to natural killer cell lysis was not respon- 
sible for the proliferation of these cells in vivo. 
When cells derived from an antibody-treated mouse were used to challenge mice, 
serotherapy with  anti-asialo  GM2  had  no  effect on  mouse  survival.  These  results 
suggest  that  serotherapy may complement a  host  anti-tumor response,  from which 
only asialo GM2 deficient cells can escape. 32  GLYCOLIPID-DEFICIENT LYMPttOMA  CELL VARIANTS 
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